Welcome to SWOG’s Spring 2015 Meeting!

This spring’s meeting brings some new opportunities along with the familiar. Once again our Hope Foundation Donor Lounge is available to Hope contributors, and you can become a contributor right at the Hope table next to the registration table. Our popular Navigating SWOG for Young Investigators session is now paralleled by a brand new Navigating SWOG for Surgical Oncologists session. And we have more opportunities for “office hour” appointments with selected industry partners than ever before, with representatives from eight companies making themselves available to meet.

On a different track, our Social Media Working Group is bringing in the founder of TheMedNet, a site connecting radiation oncologists for discussing cases and issues, and the Executive Director of The Survivor Games, a gaming-focused social network for adolescents and young adults with cancer. They should be at some of the networking events here in San Francisco.

I look forward to seeing you at our Thursday and Friday plenary sessions, where topics will include “bucket trials,” proteomics, and going global with our clinical trials. I also look forward to getting to talk to many of you informally at our Friday evening reception and other such events. Here’s to a productive and stimulating few days in San Francisco!

Sincerely,

Charles D. Blanke, M.D.
SWOG Chair
# GROUP MEETING INDEX

<table>
<thead>
<tr>
<th>Section</th>
<th>Page(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Hope Foundation</td>
<td>4 &amp; 5</td>
</tr>
<tr>
<td>Plenary Sessions</td>
<td>6, 15 &amp; 17</td>
</tr>
<tr>
<td>Office Hours and Round Table Sessions</td>
<td>7 &amp; 16-18</td>
</tr>
<tr>
<td>Hyatt Regency San Francisco Travel and Hotel Information and Hotel Maps</td>
<td>10-12</td>
</tr>
<tr>
<td>Group Meeting Supporters</td>
<td>13 &amp; 60</td>
</tr>
<tr>
<td>Schedule of Events</td>
<td>14-19</td>
</tr>
<tr>
<td>Roster of Committee Speakers</td>
<td>20-21</td>
</tr>
<tr>
<td>Administrative Committees</td>
<td>22</td>
</tr>
<tr>
<td>Committee Information</td>
<td></td>
</tr>
<tr>
<td>Adolescent and Young Adult (AYA) Committee</td>
<td>15</td>
</tr>
<tr>
<td>Barlogie-Salmon Myeloma Committee</td>
<td>15, 16 &amp; 25-26</td>
</tr>
<tr>
<td>Breast Committee</td>
<td>15, 16, &amp; 27-30</td>
</tr>
<tr>
<td>Board of Governors</td>
<td>19</td>
</tr>
<tr>
<td>Bone Marrow &amp; Stem Cell Transplantation Committee</td>
<td>17</td>
</tr>
<tr>
<td>Cancer Control and Prevention Committees</td>
<td>15 &amp; 31-41</td>
</tr>
<tr>
<td>Cancer Care Delivery Committee</td>
<td>15 &amp; 33-34</td>
</tr>
<tr>
<td>Cancer Survivorship Committee</td>
<td>15 &amp; 35</td>
</tr>
<tr>
<td>Prevention Committee</td>
<td>15 &amp; 36-38</td>
</tr>
<tr>
<td>Symptom Control and Quality of Life Committee</td>
<td>15 &amp; 39-41</td>
</tr>
<tr>
<td>Committee Chairs</td>
<td>19</td>
</tr>
<tr>
<td>Early Therapeutics and Rare Cancers Committee</td>
<td>15 &amp; 42-43</td>
</tr>
<tr>
<td>Gastrointestinal Committee</td>
<td>17, 18 &amp; 44-46</td>
</tr>
<tr>
<td>Genitourinary Committee</td>
<td>18, 19 &amp; 47-48</td>
</tr>
<tr>
<td>Imaging Committee</td>
<td>16</td>
</tr>
<tr>
<td>Leukemia Committee</td>
<td>17, 18 &amp; 49-50</td>
</tr>
<tr>
<td>Lung Committee</td>
<td>16, 18 &amp; 51-53</td>
</tr>
<tr>
<td>Lymphoma Committee</td>
<td>18, 19 &amp; 54-55</td>
</tr>
<tr>
<td>Melanoma Committee</td>
<td>16 &amp; 56-57</td>
</tr>
<tr>
<td>Pharmaceutical Sciences Committee</td>
<td>18</td>
</tr>
<tr>
<td>Radiation Oncology Committee</td>
<td>19</td>
</tr>
<tr>
<td>Surgery Committee</td>
<td>17 &amp; 24</td>
</tr>
<tr>
<td>Training &amp; Workshops</td>
<td></td>
</tr>
<tr>
<td>CRA Clinical Trials Training Course</td>
<td>14</td>
</tr>
<tr>
<td>Jeri and Noboru Oishi Symposium/Continuing Education Workshop</td>
<td>14 &amp; 23</td>
</tr>
<tr>
<td>Oncology Research Professionals (ORP) Open Forum</td>
<td>15 &amp; 23</td>
</tr>
<tr>
<td>Special Symposia</td>
<td>23-24</td>
</tr>
<tr>
<td>Future Group Meeting Dates</td>
<td>58</td>
</tr>
</tbody>
</table>

SWOG • Leading Cancer Research. Together.
The Hope Foundation supports SWOG Group Meetings.

UPCOMING FUNDING OPPORTUNITIES

- SWOG Grant Writing Workshop  Apply by May 15th
- SWOG Young Investigator Training Course  Apply by July 1st
- SWOG SEED Fund  Apply by July 1st
- SWOG/Hope Foundation Impact Award  Apply by September 1st

SEE MORE: THEHOPEFOUNDATION.ORG/RESEARCH-FUNDING

THE HOPE FOUNDATION.ORG
Because answers to cancers come from clinical trials

Please give online or at The Hope Foundation desk located in the Grand Ballroom Foyer

THF

P | 734.998.6888

SWOG • Leading Cancer Research. Together.
Thank you, Donors

Donor Lounge Hours
Thursday 7:00 am – 5:00 pm
Friday 7:00 am – 5:00
Saturday 7:00 am – 11:00 am

Continuous refreshments
Internet access
Comfortable seating

To recognize your annual gift, and provide space for meaningful dialogue

The Hope Foundation
DONOR LOUNGE
Located in Regency A
Street Level

Not yet a donor?
Visit The Hope Foundation staff across from registration to make your contribution

Every gift directly supports SWOG research

SWOG
Leading cancer research. Together.
Plenary Part I (TM)
The spring meeting’s Translational Medicine Plenary will take place Thursday, Apr 30, 2:30 - 4:30 pm, in the Grand Ballroom. Speakers and topics will include the following:

**Introductory Comments**
Lee M. Ellis, MD, SWOG Vice-Chair for Translational Medicine

**The MATCH Trial and the Future of “Bucket Trials” (or Genomic Driven Trials) Funded by CTEP**
Jeffrey Abrams, MD, National Cancer Institute Cancer Therapy Evaluation Program (CTEP)

**Stats for TM Studies and “Bucket Trials”**
Michael LeBlanc, PhD, SWOG Statistical Center

**How to Write a TM Proposal**
Daniel F. Hayes, MD, University of Michigan, & Primo “Lucky” Lara, MD, UC Davis

**Panel Discussion on Bucket Trials and TM**
Jeffrey Abrams, MD; Michael LeBlanc, PhD; Daniel F. Hayes, MD; Primo “Lucky” Lara, MD

**Hope Foundation Award: HBO in Hematopoietic Stem Cell Transplantation: Lessons Learned**
Omar Aljitawi, MD, University of Kansas Cancer Center

**A Functional Proteomics View of Cancer: Leveraging the Cancer Proteome for Cancer Trials**
Gordon Mills, MD, PhD, MD Anderson Cancer Center

Plenary Part II (General)
The spring meeting’s General Plenary will take place Friday, May 1, 12 - 2 pm, in the Grand Ballroom. Speakers and topics will include the following:

**Chair’s Welcoming and Update**
Charles D. Blanke, MD, SWOG Chair

**Best of SWOG Update: Lymphoma**
Jonathan W. Friedberg, MD, Chair, Lymphoma Committee

**Best of SWOG Update: Melanoma**
Antoni Ribas, MD, PhD, Chair, Melanoma Committee

**Best of SWOG Update: Cancer Care Delivery**
Dawn L. Hershman, MD, MS, & Scott Ramsey, MD, PhD, Co-Chairs, Cancer Care Delivery Committee

**Building International Research Capacity and Global Data Collaborations — Lessons Learned**
Yuri Quintana, PhD, Harvard Medical School

**Efforts Underway to Develop a Latin America-wide Cancer Research Network**
Thomas Gross, MD, National Cancer Institute Center for Global Health
ONE-ON-ONE & SMALL GROUP

Round Table Discussions (no advance registration needed — drop-ins welcome)
Several SWOG leaders will be available to discuss challenges and opportunities in specific subject areas and answer your questions, as detailed below.

Navigating SWOG for Surgical Oncologists
Andrew Lowy, MD, UC San Diego
Fri, May 1, 9-10 am, Board Room A

Navigating SWOG for Young Investigators
Catherine Eng, MD, SWOG PI, MD Anderson
Fri, May 1, 2-3 pm, Board Room A

Breast Committee Roundtable
Gabriel Hortobagyi, MD, MD Anderson
Fri, May 1, 3-4 pm, Board Room A

Melanoma Committee Roundtable
Alain Algazi, MD, UC San Francisco
Ken Grossman, MD, PhD, University of Utah
Sapna Patel, MD, MD Anderson
Fri, May 1, 3-4 pm, Board Room B

Industry Office Hours (advance registration needed)
A chance to meet with industry partners. Sign up for an appointment at the SWOG Registration Desk. Appointments slots are on Friday, May 1, 9 am - 12 pm and 2-5 pm.

<table>
<thead>
<tr>
<th>Company &amp; Representative(s)</th>
<th>Agents or Platforms to be Discussed</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celgene</td>
<td>Agents: Paclitaxel (Abraxane), Lenalidomide (Revlimid) and Pamilomide (Pomalyst)</td>
<td>Pacific A</td>
</tr>
<tr>
<td>Gilbert Jirau-Lucca, MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genomic Health</td>
<td>Platform: OncotypeDx - Recurrence risk assessment assay (breast, colon, prostate)</td>
<td>Pacific B</td>
</tr>
<tr>
<td>Steven Shak, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Takeda</td>
<td>Agent: Ixazomib (proteosome inhibitor)</td>
<td>Pacific C</td>
</tr>
<tr>
<td>Kelly Terrill, PharmD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lilly</td>
<td>Agents: Various</td>
<td>Pacific D</td>
</tr>
<tr>
<td>Scott Saxman, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novartis</td>
<td>Agents: Small molecule TK inhibitors including ALK, c-MET, EGFR T790M, P13K, CDK4/6, HDAC, FLT3, FGFR</td>
<td>Pacific E</td>
</tr>
<tr>
<td>Janet Lyle, PharmD, &amp;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stacie Ittershagen, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Medicine</td>
<td>Platform: FoundationOne genomic profiling</td>
<td>Pacific H</td>
</tr>
<tr>
<td>Deborah Morosini, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>Agents: MEDI4736, Tremelimumab, MEDI4736 + Tremelimumab combination, 9291, Olaparib</td>
<td>Pacific I</td>
</tr>
<tr>
<td>Aiman Shalabi, PharmD, &amp;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gregory Curt, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genentech</td>
<td>Agent: MPDL3280A (anti-PDL1)</td>
<td>Pacific J</td>
</tr>
<tr>
<td>Daniel Chen, MD, PhD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SPECIAL SESSION:
SWOG Translational Grant Opportunities with Cold Spring Harbor and Jackson Laboratories
Thur, Apr 30, 12:30-1:30 pm, Pacific K (drop-ins welcome)
All PACES/ S0820 Investigators and Staff are Invited to a PACES Update Meeting

**DATE:** Thursday, April 30, 2015

**TIME:** 4:30 pm – 5:30 pm

**LOCATION:** Marina Room

Meet the Study Coordinator, Jason Zell, DO, and get the latest information on:

- Protocol updates
- Responses to questions
- New pre-registration step to help with tracking potential participants
- Accrual strategies

Handouts of recruitment and promotional materials, snacks and drinks available.
Go Mobile at the Meeting!

To manage your Group Meeting experience from your smartphone, download our mobile guidebook. You’ll be able to plan your day with a personalized schedule and browse exhibitors, maps and general show info, all in the palm of your hand.

The guidebook app is compatible with iPhones, iPads, Android, and Blackberry devices. To get the app, use your phone’s QR-code reader to scan the code at right. Or choose one of these methods:

1. Download ‘Guidebook’ from the Apple App Store or the Android Marketplace
2. Go to m.guidebookapp.com from your Blackberry
3. Visit guidebookapp.com/getit from your phone’s browser.

Once you’ve installed the Guidebook app, search for the SWOG Spring 2015 Group Meeting Guide in the “download guides” section of the app.

Tweeting the Meeting?
Tag your Group Meeting tweets with

#swogonc

We’ll post the live stream of tagged Group Meeting updates to the SWOG website, for ease of following by those who couldn’t make it.

Follow SWOG at twitter.com/SWOG. Our username is @SWOG.
Order of Levels (Top to Bottom):
Atrium Lobby Level
Bay Level
Street Level
Pacific Concourse Level
Hyatt Regency San Francisco
5 Embarcadero Center
San Francisco, CA 94111
Phone: 415-788-1234
Fax: 415-981-3638

Arrival/Departure:
Check-in time is 3:00 p.m. Check-out time is 12:00 noon. Room amenities include a full bath, hair dryer, ironing board and iron. The concierge staff serves as a liaison between guests and the hotel and outside services.

Hotel Safety Deposit Boxes:
For your convenience, safety deposit boxes are available at the front desk for your valuables. Please do not leave valuables in your room.

Recreational Facilities:
The fitness center offers a variety of exercise equipment, free weights, treadmills, and more, exclusively for hotel guests. It is open 24 hours a day.

Hotel Restaurants and Lounges:
• Eclipse Restaurant specializes in a variety of cuisines and offers guests a relaxing atmosphere to enjoy breakfast, lunch and dinner.
• Eclipse Lounge specializes in a wide variety of cocktails, wines, beers and cognacs.
• In-room dining is available from 6:00 a.m. - 12:00 a.m. daily.

Business Center:
The Business Center is located on the Atrium Lobby level of the hotel. It is open 24 hours a day, 7 days a week. The Business Center offers fax machines, computer services, color copies, mail drop, Internet access and photocopying.

Ground Transportation:
• A taxi ride from San Francisco airport to the hotel is approximately $35.00 one-way.
• Valet parking at the hotel is $50.00 per day for hotel guests.

Temperature:
The average high for April is 65 degrees and the average low is 50 degrees.

Area Attractions:
• Alcatraz and Angel Island
• Aquarium of the Bay
• Bay Ferry Tours
• Boudin Bakery
• Cable Car Museum
• Coit Tower
• Embarcadero Center
• Farmer’s Market
• Ferry Building Marketplace
• Fisherman’s Wharf (Pier 39)
• Ghirardelli Square
• Golden Gate Bridge and Park
• Lombard Street
• Napa/Sonoma Wine Country
• San Francisco Maritime National Historical Park
• Sausalito Island
• The Exploratorium
• Yerba Buena Center for the Arts
• Yerba Buena Gardens

Local Restaurants:
(The hotel concierge can assist with reservations and suggestions)
• Alioto’s - Seafood
• Barney’s Gourmet Hamburgers - Burgers
• Boudin at the Wharf - Deli Cuisine
• Caffe Macaroni - Italian
• E’Angelo Restaurant - Italian
• Harris’ - Steaks/Chops
• Michael Mina - American
• One Market - American Regional
• Plump Jack Cafe - Eclectic
• Tadich Grill - Steak and Seafood
• The Waterfront - Seafood
CME Credit Information

Procedures for CME Credit

CME credit forms for the Group Meeting are available in the back of the Group Meeting agenda booklet. Only one form per person is required to list the CME credits for the entire meeting. Credits for each committee session are listed on the form.

Forms should be turned in to the Registration Desk before the desk closes at 11:00 a.m. on May 2, 2015. If the forms are not turned in to the desk, they can be mailed to the Operations Office the week following the Group Meeting. The Operations Office will submit all CME forms to the accrediting institution at one time. *Forms will be submitted 30 days following the meeting. You will then receive a certificate of completion in the mail following submission and processing of the CME forms by the accrediting institution.*

Group Meeting Target Audience and Educational Objectives

SWOG meets semi-annually to keep its members abreast of Group science. The target audience for these meetings are Physicians, Nurse Oncologists and Clinical Research Associates.

The educational objectives of these meetings are: to educate attendees about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments and prevention strategies that are available; to identify areas that can be improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.

These objectives apply to the following areas: Cancer Control and Prevention, including Cancer Care Delivery Committee, Symptom Control and Quality of Life Committee, Prevention Committee, Cancer Survivorship Committee and Harry Hynes Symposium; Genitourinary Committee; Early Therapeutics & Rare Cancers Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; Radiation Oncology Committee; Plenary Sessions Part I and II; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee, and Lymphoma Committee.

Continuing Medical Education Credit

The Hope Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Hope Foundation designates this live activity for a maximum of 22.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

SWOG gratefully acknowledges the support of our CME Commercial Supporters*

- **Platinum Supporters**
  - Celgene

- **Gold Supporters**
  - Eli Lilly & Co.
  - Novartis

- **Silver Supporters**
  - Bristol-Myers Squibb

- **Bronze Supporters**
  - Amgen
  - AstraZeneca

*Supporters as of March 31, 2015

Speaker and Planner CME Disclosure Information

Each speaker and planner for The Hope Foundation - CME courses has been requested to complete a Faculty Disclosure Form prior to the activity in accordance with ACCME standards. THF strives to provide accurate and up-to-date information regarding affiliations or interests that might be perceived as a potential conflict of interest for those who control CME content. Please see the disclosure handout available at the SWOG self-service and onsite registration desks. Best attempts will also be made to provide up to date information on introductory slides at each CME session.
WEDNESDAY, APRIL 29, 2015

Group Meeting Registration & Information Desk
12:00 p.m. - 5:00 p.m. - Grand Foyer (Street Level)

7:00 a.m. – 7:30 a.m.  CRA Clinical Trials Training
                        Course Check-In
                        Street Level
                        Room: Grand Ballroom Foyer

7:30 a.m. – 12:00 p.m. CRA Clinical Trials Training
                        Course
                        Street Level
                        Room: Grand Ballroom A

1:30 p.m. – 5:00 p.m. CRA Clinical Trials Training
                        Course Practicum
                        Street Level
                        Room: Grand Ballroom B

1:00 p.m. – 3:00 p.m. Nursing Research Subcommittee
                        Street Level
                        Room: Plaza Room

2:00 p.m. – 3:00 p.m. ORP Liaison Subcommittee
                        (Formerly Disease & Discipline and Research)
                        Bay Level
                        Room: Marina Room

3:00 p.m. – 4:00 p.m. SWOG Tissue Banking Meeting
                        (Invitation Only)
                        Bay Level
                        Room: Seacliff D

3:00 p.m. – 5:30 p.m. ORP Executive Committee
                        (Committee Members Only)
                        Pacific Concourse Level
                        Room: Pacific A

4:00 p.m. – 5:30 p.m. Hope Foundation Board Meeting
                        (Board Members Only)
                        Atrium Lobby Level
                        Room: Board Room A

5:30 p.m. – 7:30 p.m. Site Operations (Formerly Head CRA) - Open to Member, Affiliate and CCOP Head CRAs Only
                        Pacific Concourse Level
                        Room: Pacific DE

5:30 p.m. – 8:00 p.m. Cancer Control and Prevention
                        Executive Meeting (Committee Members Only)
                        Bay Level
                        Room: Seacliff A

6:00 p.m. – 7:00 p.m. ITSC Grant Review (Committee Members Only)
                        Bay Level
                        Room: Golden Gate

THURSDAY, APRIL 30, 2015

Group Meeting Registration & Information Desk
7:00 a.m. - 5:00 p.m. - Grand Foyer (Street Level)

Hope Foundation Information Desk
7:00 a.m. - 5:00 p.m. - Grand Foyer
Exhibits & Complimentary Coffee Service
7:00 a.m. - 4:00 p.m. - Grand Foyer

6:00 a.m. – 7:30 a.m. Crush the Crab 5K Run/2.5K Walk
                        Street Level
                        Room: Grand Ballroom Foyer

7:00 a.m. – 5:00 p.m. Hope Foundation Donor Lounge
                        (Donors Only)
                        Street Level
                        Room: Regency A

7:00 a.m. – 8:00 a.m. Advocates Committee Meeting
                        (Committee Members Only)
                        Bay Level
                        Room: Seacliff D

7:30 a.m. – 8:00 a.m. Jeri and Noboru Oishi
                        Symposium Check-In
                        Bay Level
                        Room: Grand Foyer

8:00 a.m. – 12:00 p.m. Jeri and Noboru Oishi
                        Symposium (Open Session)
                        Bay Level
                        Room: Grand Ballroom BC

NOTE: Gray Areas Indicate Workshops
and Oncology Research Professional (ORP) Sessions.
SCHEDULE OF EVENTS

THURSDAY, APRIL 30, 2015

Group Meeting Registration & Information Desk
7:00 a.m. - 5:00 p.m. - Grand Foyer (Street Level)

Hope Foundation Information Desk
7:00 a.m. - 5:00 p.m. - Grand Foyer

Exhibits & Complimentary Coffee Service
7:00 a.m. - 4:00 p.m. - Grand Foyer

8:00 a.m. – 10:00 a.m.
Atrium Lobby Level
Room: Garden Room

10:00 a.m. – 12:00 p.m.
Bay Level
Room: Seacliff D

10:00 a.m. – 12:00 p.m.
Street Level
Room: Plaza Room

10:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific D

10:00 a.m. – 12:15 p.m.
Bay Level
Room: Seacliff B-D

10:15 a.m. – 12:15 p.m.
Atrium Lobby Level
Room: Garden Room

12:00 p.m. – 2:00 p.m.
Bay Level
Room: Marina Room

12:30 p.m. – 1:30 p.m.
Pacific Concourse Level
Room: Pacific K

CANCER SURVIVORSHIP COMMITTEE

Advocates Committee Meeting
(Committee Members Only)

Quality Initiative Meeting
(Committee Members Only)

Social Media Working Group
(Working Group Members Only)

EARLY THERAPEUTICS & RARE CANCERS COMMITTEE

PREVENTION COMMITTEE

Adolescent and Young Adult (AYA) Committee

SWOG Translational Grant Opportunities with Cold Spring Harbor and Jackson Laboratories

12:30 p.m. – 2:00 p.m.
Pacific Concourse Level
Room: Pacific NO

12:30 p.m. – 2:30 p.m.
Atrium Lobby Level
Room: Garden Room

1:45 p.m. – 2:30 p.m.
Street Level
Room: Grand Ballroom Foyer

2:00 p.m. – 3:00 p.m.
Pacific Concourse Level
Room: Pacific D

2:30 p.m. – 4:30 p.m.
Street Level
Room: Grand Ballroom

4:30 p.m. – 5:30 p.m.
Bay Level
Room: Marina Room

4:30 p.m. – 7:30 p.m.
Bay Level
Room: Seacliff D

5:00 p.m. – 7:00 p.m.
Bay Level
Room: Seacliff AB

5:00 p.m. – 7:00 p.m.
Atrium Lobby Level
Room: Garden Room

5:00 p.m. – 7:00 p.m.
Street Level
Room: Plaza Room

5:30 p.m. – 6:30 p.m.
Bay Level
Room: Golden Gate

5:30 p.m. – 7:30 p.m.
Bay Level
Room: Seacliff C

ORP Open Forum

CANCER CARE DELIVERY COMMITTEE

Plenary Reception (Desserts & Coffee)

ORP Education Subcommittee
(Formerly Education & Program)

PLENARY I (Translational Medicine)

SO820 PACES Update Meeting

Myeloma Working Group
(Working Group Members Only)

Breast Working Group (Working Group Members Only)

SYMPTOM CONTROL & QUALITY OF LIFE COMMITTEE

Conflict Management Committee
(Committee Members Only)

Translational Medicine Committee Chairs Meeting
(Invitation Only)

Latin American Leadership Retreat (Invitation Only)
SCHEDULE OF EVENTS

FRIDAY, MAY 1, 2015

Group Meeting Registration & Information Desk
7:00 a.m. - 5:00 p.m. - Grand Foyer (Street Level)

Hope Foundation Information Desk
7:00 a.m. - 5:00 p.m. - Grand Foyer

Exhibits & Complimentary Coffee Service
7:00 a.m. - 4:00 p.m. - Grand Foyer

7:00 a.m. – 5:00 p.m.
Street Level
Room: Regency A

7:00 a.m. – 9:00 a.m.
Bay Level
Room: Golden Gate

7:30 a.m. – 9:30 a.m.
Atrium Lobby Level
Room: Garden Room

7:30 a.m. – 9:30 a.m.
Bay Level
Room: Marina Room

7:30 a.m. – 9:30 a.m.
Street Level
Room: Plaza Room

8:00 a.m. – 9:00 a.m.
Pacific Concourse Level
Room: Pacific F

8:00 a.m. – 11:00 a.m.
Street Level
Room: Grand A Ballroom

9:00 a.m. – 10:00 a.m.
Atrium Lobby Level
Room: Board Room A

Navigating SWOG for Surgical Oncologists (Open for Drop-Ins)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific A

Industry Office Hours: Celgene
(By Appt. only)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific B

Industry Office Hours: Genomic Health (By Appt. Only)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific C

Industry Office Hours: Takeda
(By Appt. only)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific D

Industry Office Hours: Lilly
(By Appt. only)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific E

Industry Office Hours: Novartis
(By Appt. only)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific F

Industry Office Hours: Foundation Medicine (By Appt. Only)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific G

Industry Office Hours: AstraZeneca (By Appt. Only)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific H

Industry Office Hours: Genentech (By Appt. Only)

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific I

9:00 a.m. – 12:00 p.m.
Pacific Concourse Level
Room: Pacific J

9:30 a.m. – 11:30 a.m.
Bay Level
Room: Seacliff D

Lung Working Group (Working Group Members Only)

9:30 a.m. – 11:30 a.m.
Bay Level
Room: Seacliff B-D

MELANOMA COMMITTEE

NOTE: Gray Areas Indicate Workshops and Oncology Research Professional (ORP) Sessions. Bolded Meetings Receive CME Credits

SWOG • Leading Cancer Research. Together.
FRIDAY, MAY 1, 2015

9:30 a.m. – 11:30 a.m.  
Bay Level  
Room: Bayview Room  
CANCER CONTROL AND PREVENTION OUTREACH (HARRY HYNES SYMPOSIUM)

9:30 a.m. – 11:30 a.m.  
Pacific Concourse Level  
Room: Pacific LM  
SURGERY COMMITTEE

10:00 a.m. – 11:30 a.m.  
Pacific Concourse Level  
Room: Pacific K  
Bone Marrow & Stem Cell Transplantation Committee

10:00 a.m. – 11:30 a.m.  
Pacific Concourse Level  
Room: Pacific F  
Quality Assurance Committee Meeting (Committee Members Only)

10:00 a.m. – 12:00 p.m.  
Bay Level  
Room: Marina Room  
GI Working Group (Working Group Members Only)

10:00 a.m. – 12:00 p.m.  
Bay Level  
Room: Golden Gate  
SWOG Data & Safety Monitoring Committee (Committee Members Only)

11:00 a.m. – 12:00 p.m.  
Street Level  
Room: Grand Ballroom Foyer  
Plenary Session Reception (Light Hors d’oeuvres)

12:00 p.m. – 2:00 p.m.  
Street Level  
Room: Grand Ballroom  
PLENARY II (General)

2:00 p.m. – 3:00 p.m.  
Bay Level  
Room: Marina Room  
S1316 Protocol Meeting

2:00 p.m. – 3:00 p.m.  
Bay Level  
Room: Seacliff B-D  
Lung-MAP S1400 Master Lung Protocol Update Meeting

2:00 p.m. – 3:00 p.m.  
Atrium Lobby Level  
Room: Board Room A  
Navigating SWOG for Young Investigators (Open for Drop-Ins)

2:00 p.m. – 4:00 p.m.  
Bay Level  
Room: Seacliff D  
Leukemia Working Group (Working Group Members Only)

2:00 p.m. – 5:00 p.m.  
Pacific Concourse Level  
Room: Pacific A  
Industry Office Hours: Celgene (By Appt. only)

2:00 p.m. – 5:00 p.m.  
Pacific Concourse Level  
Room: Pacific B  
Industry Office Hours: Genomic Health (By Appt. Only)

2:00 p.m. – 5:00 p.m.  
Pacific Concourse Level  
Room: Pacific C  
Industry Office Hours: Takeda (By Appt. only)

2:00 p.m. – 5:00 p.m.  
Pacific Concourse Level  
Room: Pacific D  
Industry Office Hours: Lilly (By Appt. only)

2:00 p.m. – 5:00 p.m.  
Pacific Concourse Level  
Room: Pacific E  
Industry Office Hours: Novartis (By Appt. only)

2:00 p.m. – 5:00 p.m.  
Pacific Concourse Level  
Room: Pacific H  
Industry Office Hours: Foundation Medicine (By Appt. Only)

2:00 p.m. – 5:00 p.m.  
Pacific Concourse Level  
Room: Pacific I  
Industry Office Hours: AstraZeneca (By Appt. Only)
SCHEDULE OF EVENTS

FRIDAY, MAY 1, 2015

Group Meeting Registration & Information Desk
7:00 a.m. - 5:00 p.m. - Grand Foyer (Street Level)

Hope Foundation Information Desk
7:00 a.m. - 5:00 p.m. - Grand Foyer

Exhibits & Complimentary Coffee Service
7:00 a.m. - 4:00 p.m. - Grand Foyer

2:00 p.m. - 5:00 p.m.
Pacific Concourse Level
Room: Pacific J

3:00 p.m. - 4:00 p.m.
Atrium Lobby Level
Room: Board Room A

3:00 p.m. - 4:00 p.m.
Atrium Lobby Level
Room: Board Room B

3:00 p.m. - 4:00 p.m.
Pacific Concourse Level
Room: Pacific G

3:00 p.m. - 4:30 p.m.
Bay Level
Room: Bayview A

3:00 p.m. - 5:00 p.m.
Street Level
Room: Plaza Room

3:00 p.m. - 6:00 p.m.
Atrium Lobby Level
Room: Garden Room

3:30 p.m. - 6:30 p.m.
LUNG COMMITTEE
Street Level
Room: Grand Ballrom A

4:00 p.m. - 6:00 p.m.
Pharmaceutical Sciences Committee
Pacific Concourse Level
Room: Pacific M

4:00 p.m. - 6:00 p.m.
Lymphoma Working Group
Pacific Concourse Level
Room: Pacific F

4:00 p.m. - 6:00 p.m.
GI COMMITTEE
Street Level
Room: Grand Ballroom B

4:00 p.m. - 6:00 p.m.
LEUKEMIA COMMITTEE
Street Level
Room: Grand Ballroom C

6:45 p.m. - 8:00 p.m.
Reception
Atrium Lobby Level
Room: Atrium 3-5

NOTE: Gray Areas Indicate Workshops and Oncology Research Professional (ORP) Sessions. Bolded Meetings Receive CME Credits
SATURDAY, MAY 2, 2015

Group Meeting Registration & Information Desk
7:00 - 11:00 a.m. · Grand Foyer (Street Level)

Hope Foundation Information Desk
7:00 - 11:00 a.m. · Grand Foyer

7:00 a.m. – 11:00 a.m.
Street Level
Room: Regency A
Hope Foundation Donor Lounge
(Donors Only)

7:00 a.m. – 8:00 a.m.
Street Level
Room: Grand Ballroom B
Board of Governors (Board Members Only)

8:15 a.m. – 9:15 a.m.
Street Level
Room: Grand Ballroom B
Committee Chairs (Committee Members Only)

9:30 a.m. – 10:30 a.m.
Bay Level
Room: Marina Room
NCORP PI Meeting

9:30 a.m. – 11:00 a.m.
Bay Level
Room: Seacliff D
RADIATION ONCOLOGY COMMITTEE

9:30 a.m. – 12:30 p.m.
Street Level
Room: Grand Ballroom C
LYMPHOMA COMMITTEE

9:30 a.m. – 12:30 p.m.
Street Level
Room: Grand Ballroom A
GU COMMITTEE

10:00 a.m. – 11:00 a.m.
Street Level
Room: Plaza Room
VA Working Group Meeting
(Invitation Only)
Roster of Committee Speakers

Thursday, April 30, 2015

**Cancer Survivorship Committee, 8:00 a.m. - 10:00 a.m. - Garden Room**
Sarcoma Survivorship Focus Group Progress Report – Lara Davis, M.D., Co-Chair, Sarcoma Survivorship Focus Group

Can Cardiac Disease in Osteogenic Sarcoma Survivors be Predicted with Morphomics? – Laurence H. Baker, D.O., Co-Chair, Sarcoma Survivorship Focus Group

**Early Therapeutics Committee, 10:00 a.m. - 12:15 p.m. - Seacliff B-D**
New Developments in Early Therapeutics – Monica Mita, M.D., Cedars-Sinai Medical Center

Bayer Healthcare Oncology Pipeline and Lifecycle Management – Scott Wilhelm, Ph.D., Global Medical Affairs Scientist, Medical Affairs Oncology, Bayer Healthcare

Anti-CTLA-4 Plus Anti PD-1 in Rare Tumors – Sandip Patel, M.D., Northwestern University

A Trial Incorporating Upfront Targeted Therapy in Carcinoma of Unknown Primary – Laurence H. Baker, D.O. and Erin F. Cobain, M.D., University of Michigan

**Prevention Committee, 10:15 a.m. - 12:15 p.m. - Garden Room**
Epigenetics and Diet in Cancer Prevention – Dr. Sharon Ross, National Cancer Institute

**Cancer Care Delivery Committee, 12:30 p.m. - 2:30 p.m. - Garden Room**
New SEER Initiatives – Lynn Penberthy, National Cancer Institute

Comparative Effectiveness Studies in Surgical and Gynecologic Oncology - Moving from Observational Studies to Intervention – Jason Wright, M.D., Columbia University

Management of HBV in Cancer Patients – Jessica Hwang, M.D., MD Anderson Cancer Center

Long Term Consequences of Intermittent and Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer - SWOG Medicare Analysis Results – Dawn Hershman, M.D., M.S., Columbia University

Friday, May 1, 2015

**Breast Committee, 8:00 a.m. - 11:00 a.m. - Grand A Ballroom**
DNA Repair Deficiency as a Model for Synthetic Lethal Approaches – Alan Ashworth, Ph.D., F.R.S., University of California at San Francisco

Chemotherapy with or without PARP Inhibition for Triple Negative Breast Cancer: Matching Phenotype to Activity – Eve Rodler, M.D., University of California, Davis

Characterization of DNA Repair Deficiency Biomarkers and Applications in the Adjuvant Setting – Priyanka Sharma, M.D., D. Phil, University of Kansas Cancer Center
Roster of Committee Speakers

Breast Committee (cont’d)
PARP Inhibition and Radiation Therapy to Minimize Local Recurrence – Reshma Jagsi, M.D., University of Michigan

Harry E. Hynes Symposium, 9:30 a.m. - 11:30 p.m. - Bayview Room
Social Media and Oncology Care: An Overview – Michael Fisch, M.D., MD Anderson Cancer Center

The Intersection of Palliative Care with Oncology – Thomas J. Smith, M.D., John Hopkins Hospital

Melanoma Committee, 9:30 a.m. - 11:30 a.m. - Seacliff B-D
Assessment of Immune Cell-Melanoma Interactions to Decide on How to Treat Melanoma – Paul C. Tumeh, M.D., University of California, Los Angeles

Surgery Committee, 9:30 a.m. - 11:30 a.m. - Pacific MN
Biological Effects of Minimally Invasive Oncological Surgery – Juan Cata, M.D., MD Anderson Cancer Center

Phase III Trial Evaluating the Oncologic Safety of Laparoscopic Versus Open Liver Resection – Claudius Conrad, M.D., MD Anderson Cancer Center

Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction – Robert S. Krouse, M.D., University of Arizona College of Medicine

Update on S1011: Comparing Extended Vs. Standard Lymphadenectomy with Radical Cystectomy for Invasive Bladder Cancer – Seth Lerner, M.D., Baylor College of Medicine

Update on S0820: A Double Blind Randomized Placebo-Controlled Trial of DFMO and Sulindac to Prevent Recurrence of Adenomas in Patients with Stages I-III Colon Cancer, Phase III – Jason Zell, D.O., University of California, Irvine

Gastrointestinal Committee, 4:00 p.m. - 6:00 p.m. - Grand B Ballroom
A Structured Approach to Prioritizing Cancer Research Using Stakeholders and Value of Information – Scott Ramsey, M.D., Ph.D., Fred Hutchinson Cancer Research Center

Leukemia Committee, 4:00 p.m. - 6:00 p.m. - Grand C Ballroom
Genetics, Epigenetics and Non-Coding RNAs: Can We Design a Molecular Risk-Adapted Trial for Older AML – Guido Marcucci, M.D., Gehr Leukemia Center

Saturday, May 2, 2015

GU Committee, 9:30 a.m. - 12:30 p.m. - Grand A Ballroom
A Structured Approach to Prioritizing Cancer Research Using Stakeholders and Value of Information – Scott Ramsey, M.D., Ph.D., Fred Hutchinson Cancer Research Center
SWOG ADMINISTRATIVE COMMITTEES

Adolescent & Young Adults
Chair: Brandon M. Hayes-Lattin, M.D.

Board of Governors
Chair: Charles D. Blanke, M.D.

Bone Marrow and Stem Cell Transplantation Committee
Chair: Patrick Stiff, M.D.

Conflict Management Committee
Chair: Vernon K. Sondak, M.D.

Data & Safety Monitoring Committee
Chair: Lawrence E. Flaherty, M.D.

Imaging Committee
Chair: Lawrence H. Schwartz, M.D.

Membership Committee
Chair: James K. Weick, M.D.

Oncology Research Professionals Committee
Chair: Keisha C. Humphries, R.N., B.S.N.

Patient Advocates Committee
Chair: Rick Bangs

Pharmaceutical Sciences Committee
Co-Chair: Siu-Fun Wong, Pharm.D.
Co-Chair: Susan Kadlubar, Ph.D.

Professional Review Committee
Chair: Primo N. Lara, Jr., M.D.

Quality Assurance Committee
Chair: Manuel Valdivieso, M.D.

Radiation Oncology Committee
Chair: Paul Okunieff, M.D.

Surgery Committee
Chair: George H. Yoo, M.D.
Special Symposia

Jeri and Noboru Oishi Symposium
Thursday, April 30, 2015 · 8:00 a.m. · 12:00 p.m.
Location: Grand Ballroom BC (Street Level)

Featured Speakers:
- The Ins and Outs of a FDA Audit · Jane Kreis
- Symptom Management for Patients Taking Duloxetine · Norah Lynn Henry, M.D., Ph.D.
- Ensuring Oral Compliance · Paula Fulgham, R.N., O.C.N.
- Duloxetine for Aromatase Inhibitor · How Does it Work · Lara Au, Pharm.D., B.C.O.P.

This activity has been submitted to the Oncology Nursing Society for approval to award contact hours. ONS is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s COA.

Certificates for continuing education credits (CEUs) will be distributed to attendees upon completion and return of their evaluation sheets. Certificates of attendance will be given for Society of Clinical Research Associates.

Oncology Research Professionals Open Forum
Thursday, April 30, 2015 · 12:30 p.m. · 2:00 p.m.
Location: Pacific NO (Pacific Concourse Level)

Topic: This forum offers an opportunity to get answers to your clinical trial questions and address the science and technical research issues that challenge us today.

Featured Topics:
- Quality Assurance Audits
- Regulatory Affairs
- Data Management Tips & Tools for ORPs
- CTCAEs v4.0 and SAE Q&A
- Cancer Treatment Modalities Q&A
- Specimen Preparation and Shipment
- SWOG Federal Reimbursements
- SWOG CTI Non-Federal Reimbursements
- Hot Topics in Site Administration
- General Recruitment and Adherence
Special Symposia

Surgery Committee
Friday, May 1, 2015 - 9:30 a.m. - 11:30 a.m.
Location: Pacific LM (Pacific Concourse Level)

Featured Speakers and Topics:

• Biological Effects of Minimally Invasive Oncological Surgery
  Juan Cata, M.D., MD Anderson Cancer Center

• Phase III Trial Evaluating the Oncologic Safety of Laparoscopic Versus Open Liver Resection
  Claudius Conrad, M.D., MD Anderson Cancer Center

• Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
  Robert S. Krouse, M.D., F.A.C.S., Staff General and Oncologic Surgeon, Southern Arizona VA Health Care System, Professor of Surgery, University of Arizona College of Medicine

• Update on S1011: Comparing Extended Vs. Standard Lymphadenectomy with Radical Cystectomy for Invasive Bladder Cancer
  Seth Paul Lerner, M.D., Professor, Department of Urology, Baylor College of Medicine

• Update: S0820: A Double Blind Randomized Placebo-Controlled Trial of DFMO and Sulindac to Prevent Recurrence of Adenomas in Patients with Stages I-III Colon Cancer, Phase III
  Jason A. Zell, D.O., Assistant Professor, Division of Hematology/Oncology, Departments of Medicine & Epidemiology, University of California, Irvine
BARLOGIE-SALMON MYELOMA COMMITTEE

Committee Leadership
Chair: Robert Z. Orlowski, M.D., Ph.D.
Vice-Chair: Brian G.M. Durie, M.D.
Executive Officer: Susan M. O’Brien, M.D.
Statisticians: Antje Hoering, Ph.D.
Rachael Sexton, M.S.

Scientific Leadership
Translational Medicine:
Radiation: Joshua Epstein, D.Sc.
Srinivasan Vijayakumar, M.D.

Surgery: J. Sybil Biemann, M.D.
Saad Z. Usmani, M.D.
Eric M. Rohren, M.D., Ph.D.
Robert B. Lorsbach, M.D., Ph.D.
Frits van Rhee, M.D., Ph.D.

Pathology: Robert B. Lorsbach, M.D., Ph.D.

Early Therapeutics:
Designates: NCORP Representative:
Data Coordinators:
Oncology Research Professionals:
CRAs:
Ellen Chase, B.S.

Nurses:
Deborah A. Halk, R.N.
Steven M. Burt, NP-C

Patient Advocate:
Jack Aiello

Pharmaceutical Science:
Lara M. Au, Pharm.D.
Craig Elg, Pharm.D.

Protocol Coordinator:
Cara Laubach, M.I.I.M.

Time/Location
Friday, May 1, 2015
Room: Garden Room (Atrium Lobby Level)
7:30 a.m. - 9:30 a.m.

Agenda
Presentations
Active Studies
- CTSU/E1A11, “Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (Vrd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CrD) Followed by Limited or Indefinite DURation Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).” Dr. Zonder. Activated by ECOG: 11/13/13; Activated by SWOG: 2/1/14.

Closed Studies
- S0777, “A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant.” Drs. Durie, Barlogie, Abidi, and Epstein. Activated: 2/28/08; Closed: 2/1/12.

Proposed Studies
- SXXXX, “Randomized Phase III Study of Lenalidomide (L) vs. Lenalidomide + Ixazomib (Ll) (NSC-XXXX) as Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma (MM).” Dr. Shah.
- SXXXX, “Amyloid transplant eligible vs. ineligible.” Dr. Scott.

Working Groups
Amyloidosis Working Group update
BARLOGIE-SALMON MYELOMA COMMITTEE

Waldenström’s Working Group update
Myeloma Translational Medicine Subcommittee update

Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts
No publication information for this cycle.

Submitted Manuscripts


BREAST COMMITTEE

Committee Leadership
Chair: Gabriel N. Hortobagyi, M.D.
Vice-Chair: Debasish Tripathy, M.D.
Executive Officer: Julie R. Gralow, M.D.
Statisticians: William E. Barlow, Ph.D.
Danika Lew, M.A.

Scientific Leadership
Translational Medicine: Daniel F. Hayes, M.D.
Radiation Oncology: Reshma Jagsi, M.D.
Surgery: Christine Lee, M.D.
Imaging: Anne F. Schott, M.D.
Wei Tse Yang, M.B.B.S.
Pathology: Allen M. Gown, M.D.
Peggy L. Porter, M.D.
George Somlo, M.D.

Early Therapeutics:
Designates
Cancer Control Liaisons: Carol J. Fabian, M.D. (Cancer Survivorship)
Dawn L. Hershman, M.D. (Cancer Care Delivery)
Melanie R. Palomares, M.D. (Prevention)
Helen K. Chew, M.D. (Symptom Control & QOL)

CCOP Representative: Melanie E. Royce, M.D., Ph.D.
Data Coordinators: Jean Barce
Jennie Barrett
Larry Kaye
Iris Syquia
Louise Highleyman

Oncology Research Professionals:
CRAs: Karyn N. Hart, C.C.R.P.
Pamela A. Williams, R.N., M.S.N.
Nurses: Dorothy Coleman, R.N., M.S.
Kathy L. Czaplicki, R.N., M.S.N.
Patient Advocate: Nancy Singleton
Pharmaceutical Science: Jessie Modlin, Pharm.D.
Rivka Siden, Pharm.D.
Protocol Coordinator: Megan Hardin

Agenda
8:00 – 8:05 am Welcome and introductions – Gabriel Hortobagyi, M.D. and Debu Tripathy, M.D.
8:05 – 9:20 am Breast Committee Mini-Symposium “Exploiting DNA Repair Deficiency”
8:05 – 8:30 am DNA Repair Deficiency as a Model for Synthetic Lethal Approaches – Alan Ashworth, Ph.D., FRS – University of California at San Francisco
8:30 – 8:40 am Chemotherapy with or without PARP Inhibition for Triple Negative Breast Cancer: Matching Phenotype to Activity – Eve Rodler, M.D.
8:40 – 8:50 am Characterization of DNA Repair Deficiency Biomarkers and Applications in the Adjuvant Setting – Priyanka Sharma, M.D., D. Phil
8:50 – 9:00 am PARP inhibition and Radiation Therapy to Minimize Local Recurrence – Reshma Jagsi, M.D.
9:00 – 9:20 am Panel discussion and audience Q & A
9:20 – 9:30 am Publications update – Bill Barlow, Ph.D.
9:30 – 10:00 am Update of open SWOG and CTSU trial - All
10:00 – 10:20 am Studies in Development - All
10:20 – 10:35 am Reports from Committee Liaisons Radiotherapy - Reshma Jagsi, M.D.
Surgery - Christine Lee, M.D.
Cancer Survivorship - Carol Fabian, M.D.
Health Disparities - Dawn Hershman, M.D.
Prevention - Melanie Palomares, M.D.
NCORP (NCI Community Oncology Research Program) Update – Melanie Royce, M.D.
Patient Advocate – Nancy Singleton
10:35 – 10:45 am Translational Medicine Sub-Committee – Daniel Hayes, M.D.
10:45 – 11:00 am New Business – All
11:00 am Adjourn

Active Adjuvant Studies
- S1007, “A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.” Drs. Gralow, Kalinsky, Meric-Bernstam, Hortobagyi, Albain and Barlow. Activated: 1/15/11.

Time/Location
Friday, May 1, 2015
Room: Grand A Ballroom (Street Level)
8:00 a.m. - 11:00 a.m.
BREAST COMMITTEE


- CTSU/NSABP B-55, “A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.” Dr. Sharma. Activated: 7/3/14.

Active Advanced Disease Studies


- CTSU/E3108, “A Phase II Prospective Trial Correlating PFS with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen.” Dr. Lohrisch. Activated: 10/8/10.

Active Cancer Control Studies


Closed Studies


- S0230, “Phase II Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer.” Drs. Moore and Albain. Activated: 10/1/03; Closed: 6/1/11.


- S1008, “Feasibility Study of a Physical Activity and Dietary Change Weight Loss Intervention in Breast and Colorectal Cancer Survivors Phase II.” Drs. Greenlee and Hershman. Activated: 3/1/12; Closed: 7/1/14.


Studies in Development

- S1410, “Randomized Trial of Interval Increase in Exercise Intensity vs Moderate Intensity Exercise to Improve Cardiopulmonary Fitness in Breast Cancer Survivors Participating in a Weight Loss Intervention.” Dr. Klemp.
BREAST COMMITTEE

- **S1411**, "Phase II Randomized Trial of Adjuvant Vaccine Therapy in Patients with High-Risk HER2-Positive Breast Cancer." Dr. Mittendorf.

- **S1416**, "Phase II Randomized Trial of Cisplatin/Vinorelbine with or without Veliparib (ABT-888) in Metastatic Triple Negative Breast Cancer (TNBC) and BRCA Mutation-Associated Breast Cancer." Drs. Rodler and Sharma.

- **S1418**, "A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (pNmic) After Neoadjuvant Chemotherapy." Drs. Pusztai, Sharma and Mammen.


- **S1506**, "Phase II Randomized Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab With or Without Paclitaxel in Her2+ Metastatic Breast Cancer (MBC)." Dr. Elias.

- **S1509**, "A Phase II Study of Veliparib Administered Concurrently with Radiotherapy for Inflammatory or High-Risk Triple-Negative Breast Cancer to A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Veliparib Administered Concurrently with Radiotherapy for Inflammatory or High-Risk Triple-Negative Breast Cancer." Dr. Jagsi.

- **S1510**, "A Randomized Phase II Study of Liposomal Doxorubicin vs Combination Therapy with Liposomal Doxorubicin and Temsirolimus (+/- Bevacizumab) for the Treatment of Patients with Locally Advanced or Metastatic Metaplastic/Mesenchymal Breast Cancer for which Curative Therapy is not Available." Dr. Moulder.

**New Proposals**

- "Randomized Phase II Study of TDM-1 vs. TDM-1 and Continuous Low-Dose Temozolomide in 1-4 HER-2+ Breast Cancer Brain Metastases Following Stereotactic Radiosurgery with Phase 1 Lead-in Study." Drs. Tsien and Conlin.

**Publications**

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

**Published/Accepted Manuscripts**


- **S0927** Randomized placebo-controlled trial of omega-3-fatty acid for the control of aromatase inhibitor-induced musculoskeletal pain (S0927). DL Hershman, JM Unger, KD Crew, D Awad, SR Dakhil, H Greenlee, L Hansen, DL Lew, LM Minasian, C Till, JL Wade, FL Meyskens, CM Moinpour. Journal of Clinical Oncology, accepted 1/20/15. [also under SCQOLCommittee]


- **C40302** Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib


Submitted Manuscripts


# CANCER CONTROL & PREVENTION COMMITTEES

<table>
<thead>
<tr>
<th><strong>Committee Leadership</strong></th>
<th><strong>Designates</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Assoc. Chair for Cancer Control &amp; Prevention:</td>
<td>Oncology Research Professionals:</td>
</tr>
<tr>
<td>Committee Leadership</td>
<td>CRAs:</td>
</tr>
<tr>
<td>Cancer Care Delivery Co-Chairs:</td>
<td>Connie Szczepanek, R.N., B.S.N.</td>
</tr>
<tr>
<td>Cancer Survivorship Co-Chairs:</td>
<td>Joyce N. Tull, R.N., B.S.N.</td>
</tr>
<tr>
<td>Symptom Control &amp; QOL Co-Chairs:</td>
<td>Micheal F. Stephens, C.C.R.A.</td>
</tr>
<tr>
<td>Executive Officer:</td>
<td>Mindy Whisnant, C.C.R.P.</td>
</tr>
<tr>
<td>Statisticians:</td>
<td></td>
</tr>
<tr>
<td>Administrative Lead (Stat Ctr):</td>
<td>Pharmaceutical Science Committee:</td>
</tr>
<tr>
<td>Administrative Lead (UCI):</td>
<td>Manj Randhawa, Pharm.D.</td>
</tr>
<tr>
<td>Scientific Leadership</td>
<td>Siu-Fun Wong, Pharm.D.*</td>
</tr>
<tr>
<td>NCORP Representative:</td>
<td>Susan A. Kadlubar, Ph.D.</td>
</tr>
<tr>
<td>Radiation Therapy Committee:</td>
<td>Statistical Center Support:</td>
</tr>
<tr>
<td>Surgery Committee:</td>
<td>Karen Anderson*</td>
</tr>
<tr>
<td>Translational Medicine:</td>
<td>Monica Yee, C.C.R.P.*</td>
</tr>
<tr>
<td>Liaisons:</td>
<td>Dona Marrah, C.C.R.P.</td>
</tr>
<tr>
<td>Breast Committee:</td>
<td>Diane Liggett*</td>
</tr>
<tr>
<td>Gastrointestinal Committee:</td>
<td>Roxanne Topacio, C.C.R.P.*</td>
</tr>
<tr>
<td>Gastrointestinal Committee Colon:</td>
<td>*Executive Committee Members and Staff</td>
</tr>
<tr>
<td>Genitourinary Committee:</td>
<td>Patient Advocates:</td>
</tr>
<tr>
<td>International Liaison:</td>
<td>Anna Gottlieb</td>
</tr>
<tr>
<td>Lung Committee:</td>
<td>Amy Geschwender, Ph.D.</td>
</tr>
<tr>
<td>Lymphoma Committee:</td>
<td>Protocol Coordinator (Cancer Care Delivery Cmte):</td>
</tr>
<tr>
<td>Melanoma Committee:</td>
<td>Patricia O’Kane*</td>
</tr>
<tr>
<td></td>
<td>Protocol Coordinator (Survivorship; Symptom Control and QOL Cmtes):</td>
</tr>
<tr>
<td></td>
<td>Kimberly Kaberle*</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>*Executive Committee Members and Staff</td>
<td></td>
</tr>
</tbody>
</table>
CANCER CONTROL & PREVENTION COMMITTEES

Harry E. Hynes NCORP Symposium (Joint Session)

Friday, May 1, 2015
Room: Bayview Room (Bay Level)
9:30 a.m. – 11:30 a.m.

Agenda

10:00 – 10:05 a.m. WELCOME
Mark O’Rourke, M.D.

10:05 – 10:15 a.m. Associate Chair Report
Frank L. Meyskens, M.D.

10:15–10:40 a.m. Social Media and Oncology Care: An Overview
Mike Fisch, M.D.

10:40 – 10:50 a.m. Questions

10:50 – 11:20 a.m. The intersection of palliative care with oncology
Thomas J. Smith, M.D.

11:20 a.m. – 11:30 a.m. Questions

11:30 a.m. – 11:45 a.m. Highlighted studies by CC&P Co-Chairs
Frank Meyskens, Jr., M.D.

11:45 a.m. – 12:00 p.m. Open Forum for NCORP Investigators
Mark O’Rourke, M.D.
CANCER CARE DELIVERY COMMITTEE

Cancer Care Delivery Committee Co-Chairs:
Dawn L. Hershman, M.D., M.S.
Scott D. Ramsey, M.D., Ph.D.

Time/Location
Thursday, April 30, 2015
Room: Garden Room (Atrium Lobby Level)
12:30 p.m. - 2:30 p.m.

Agenda

Presentations/Concepts:
New SEER Initiatives – Lynn Penberthy, NCI
Comparative Effectiveness Studies in Surgical and Gynecologic Oncology – moving from observational studies to intervention – Jason Wright, M.D., Columbia University
Management of HBV in cancer patients – new concept – Jessica Hwang, M.D., MD Anderson Cancer Center
Long Term Consequences of Intermittent and Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer – SWOG Medicare Analysis Results – Dawn Hershman, M.D., M.S. Columbia University

Active Studies
- S1007, “Update on Quality of Life and Economic Analysis Sub-study of Breast protocol S1007.” Dr. Barlow.

Concepts approved by DCP
- S1417, “Implementation of a Prospective Financial Toxicity Assessment Tool in Patients with Metastatic Colorectal Cancer.” Update on Concept. Dr. Shankaran.

Ongoing Database/Grant Funded Projects
- Medicare claims data as a core resource for comparative effectiveness studies. Dr. Hershman and Joseph M. Unger, Ph.D.
- Value of Information and SWOG Trials, PCORI Project. Drs. Ramsey and Carlson.

Studies Closed To Accrual
- S1105, “Randomized Controlled Trial of a Behavioral Intervention to Improve Adherence to Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer.” Drs. Hershman and Neugut.

Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts
- The diffusion of docetaxel use in patients presenting with metastatic prostate cancer. J Unger, D Hershman, D Martin,
CANCER CARE DELIVERY COMMITTEE


Submitted Manuscripts


CANCER SURVIVORSHIP COMMITTEE

Cancer Survivorship Committee Co-Chairs:
Carol J. Fabian, M.D.
Robert S. Krouse, M.D.

Time/Location
Thursday, April 30, 2015
Room: Garden Room (Atrium Lobby Level)
8:00 a.m. - 10:00 a.m.

Agenda

Welcome New Member to Survivorship: Benjamin Powers, M.D.

Presentation: Lara Davis M.D., Co-Chair Sarcoma Survivorship Focus Group: Progress Report

Presentation: Laurence H. Baker D.O., Co-Chair Sarcoma Survivorship Focus Group: Can Cardiac Disease in Osteogenic Sarcoma Survivors be Predicted with Morphomics?

Update of Concepts Previously Proposed

- S1501, “Carvedilol vs Placebo to Decrease the Incidence of Left Ventricular Myocardial Dysfunction in High Risk Patients with Metastatic Breast Cancer on Trastuzumab Therapy.” (Secondary Committee Breast) Drs. Floyd and Leja (TM components Goodwin and Fabian).

- Cancer Survivorship Website Project. Drs. O’Rourke, Klemp, and Neuhouser. Update progress and timeline.

- Docosahexaenoic Acid (DHA) vs Placebo during Adjuvant Therapy for Prevention of Cognitive Dysfunction. (Secondary Committee Breast). Drs. Fabian and Wefel.

Activated Studies

- C70807, “The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance.” Dr. Van Veldhuizen. Cancer Control Credits: 0.2 ($400) at pre-registration, 0.8($1,600) at enrollment. Activated: 6/11/11. Update status.


Closed Studies

- S1008, “Pilot and Feasibility Study of a Physical Activity and Dietary Change Weight Loss Intervention in Breast and Colorectal Cancer Patients.” Dr. Greenlee. Activated: 3/1/12; Closed: 7/1/14. Cancer Control Credits: 1.0

New Concepts

- Quality of Life After Surgical Treatment of Rectal Cancer: A Pilot Study. Dr. Carmichael.

- Translating Ideas from the International Survivorship Group to SWOG Concepts. Dr. Albain.

Special Projects/ Presentations

- Rick Bangs and Anna Gottlieb: Advocate Update.

- Martine Extermann, MD, PhD: Everolimus Working Group Update.

- Connie Szczepanek, RN, BSN: Oncology Research Professionals Update.

- Carol Fabian, MD and Robert Krouse, MD: Discussion on committee efforts on energy balance.

Other Business

Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts


Submitted Manuscripts

No publication information for this cycle.
PREVENTION COMMITTEE

Prevention Committee Co-Chairs:
Powel Brown, M.D., Ph.D.
Marian Neuhouser, Ph.D., R.D.

Time/Location
Thursday, April 30, 2015
Room: Garden Room (Atrium Lobby Level)
10:15 a.m. - 12:15 p.m.

Agenda

Introduction

Presentations:
1. Opening Comments - Dr. Marian Neuhouser
2. Epigenetics and Diet in Cancer Prevention - Dr. Sharon Ross
3. Panel discussion: Dietary Interventions for Cancer Prevention - Drs. Ross, Neuhouser, Goodman

Active Studies


Closed Studies

New Business

Concepts under development:
2. Combination therapy for the prevention of breast cancer: Bazedoxifene plus estrogen. Dr. Fabian.
4. Omega-3 plus metformin for breast cancer prevention. Dr. Crew.

New Concepts to discuss:
1. Open discussion

Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts

PREVENTION COMMITTEE


■ S9217 Intraprostatic inflammation is positively associated with serum PSA in men with PSA < 4 ng/mL, normal DRE, and negative for prostate cancer. MH Umbehr, B Gurel, TJ Murtola, S Sutcliffe, SB Peskoe, CM Tangen, PJ Goodman, IM Thompson, SM Lippman, M Scott Lucia, HL Barnes, CG Drake, WG Nelson, AM De Marzo, EA Platz. Prostate Cancer and Prostatic Diseases, in press.

■ S9217 Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. CM Heaphy, G Gaonkar, SB Peskoe, CM Tangen, PJ Goodman, SM Lippman, IM Thompson, Jr., EA Platz, AK Meeker. Prostate, in press.
Submitted Manuscripts

S0000 Multiethnic fine-mapping of prostate cancer susceptibility regions. Y Han, DJ Hazlett, FWiklund, FSchumacher, DOSTram, SIBerndt, ZWang, KRand, RNHoover, MJMachiela, MYeager, LBurdette, CCChung, AHutchinson, KYu, JXu, RCTravis, TJKey, ASiddiqi, FCantzian, ATakahashi, MKubo, JLSanford, SKolb, SMGapstur, WRDiver, VLStevens, SSStrom, CPettaway, AAIOlama, ZKote-Jarai, REeles, EDEYeboah, YTettey, RBiritwum, AAAdjei, ETay, ATruelove, SNiwa, Apchokalingam, WBSisaacs, CCChung, ACHutchinson, KYu, JXu, RCTravis, TJKey, ASiddiqi, FCantzian, ATakahashi, MKubo, JLSanford, SKolb, SMGapstur, WRDiver, VLStevens, SSStrom, CPettaway, AAIOlama, ZKote-Jarai, REeles, EDYEyeboah, YTettey, RBBiritwum, AAAdjei, ETay, ATruelove, SNiwa, APChokalingam, WBSisaacs, CChen, SLindstrom, LLeMarchand, ELGiovannucci, MPomerantz, HLong, FLi, JMMa, MStampfer, EJohn, SIngles, RAKittles, ABMurphy, WBlot, LBSignorell, WZheng, DAlbanes, JVirtamo, SWeinstein, BNemesure, JCarpten, CLeske, SYWu, AJMHennis, BARybicki, CNeslund-Dudas, AWHsing, LChu, PGoodman, EAKein, SLZheng, JWitte, GCasey, ERiboli, QLi, MFreedman, DJHunter, HGronberg, TheGAME-ONELLIPSEConsortium, MBCook, HKakagawa, PKraft, SJChanock, DFCeaston, BEHenderson, DConti, GACoetzee, CAHaiman. PLOSGenetics, submitted 3/15.

S0000 Methodological considerations related to genome-wide assessments of height heritability in a large sample of African ancestry adults. FChen, JHe, JZhang, GKCchen, VThomas, CBAmbrsone, EVBandera, SIBerndt, LBernstein, WJBlot, QCai, JCarpten, GCasey, SJCchanock, ICcheng, LChu, SLDeming, WRDriver, PGGoodman, RBHayes, AJMHennis, AJSingh, JHJHu, SAIngles, EMJoh, RAkittles, SKolb, MCLeske, RCCMillikan, KRMorone, AMurphy, BNemesure, CNeslund-Dudas, SNyantey, EAOstrander, MFPress, JLRodriguez-Gil, BARybicki, FSchumacher, JLSanford, LSBsignorell, SSSrostrom, MThun, DVanDenberg, ZWang, JSWitte, SYWu, YYamamuro, WZheng, RGZiegler, AHStram, LNkolonel, LLeMarchand, BEHenderson, CACHaiman, DOSTram. PLOSONE, under review.

S0000 A novel risk variant at the 8q24 prostate cancer susceptibility region in men of African ancestry. YHan, KARand, DJHazlett, SASIngles, RAKittles, SSStrom, BARybicki, BNemesure, WBSisaacs, JLSanford, WZheng, FSchumacher, SIBerndt, ZWang, JXu, NRohland, DReich, ATandon, BPasaniuc, AAllen, DQuinque, SMallick, DNotiri, MRosenfeld, JRJayani, SKolb, SMGapstur, VLStevens, CPettaway, EDYeboah, YTettey, RBiritwum, AAAdjei, ETay, ATruelove, SNiwa, APChokalingam, EMJoh, ABMurphy, LSBsignorell, JCarpten, CLeske, SYWu, AHennis, CNeslund-Dudas, AWHsing, LChu, PGoodman, EAKein, SLZheng, JWitte, GCasey, SKagwga, ALubwama, LCPooler, XSheng, GACoetzee, MBCook, SJChanock, DOStram, SWatya, WJBlot, DConti, BEHenderson, CAHaiman. AmericanJournalofHumanGenetics, submitted 3/15.

S9217 Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. CHChau, DDKprice, CTill, PJGoodman, XChen, RJLeach, TLJohnson-Pais, AWHsing, AHoque, CMTang, LChu, HLParn, JMSchenk, JKVReichardt, IMThompson, WDfigg. PLOSONE, resubmitted/under review.

S9217 Association between serum fatty acids and intraprostatic inflammation in the placebo arm of the Prostate Cancer Prevention Trial. SHNash, JMSchenk, ARKristal, PJGoodman, MSLucia, HLParn, IMThompson, SMlippman, BGurel, AMDemarzo, EAPlatz. CancerPreventionResearch, resubmitted/under review.

S9217 Prostate cancer risk assessment by genetic risk score in men with or without family history. HChen, XIliu, CBrendler, DPAnkerst, RJLeach, PJGoodman, MSLucia, CTang, LWang, FCChi, JSun, AKKader, WB Isaacs, BTIfford, SLZheng, IMThompson, EAPlatz. JournaloftheNationalCancerInstitute, submitted 3/15.

S9217 Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. DWinchester, CTill, PJGoodman, CTang, RSantella, RJLeach, JXu, SZheng, IMThompson, MSLucia, SMlippman, HLParnes, PDzuziakiewicz, WBSisaacs, AMDeMarzo, CGDrake, EAPlatz. Prostate. submitted 3/15.

S9217 Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis. DAWinchester, BGurel, CTill, PJGoodman, CTang, RM Santella, TParis-Johnson, RJLeach, IMThompson, JXu, SLZheng, MSLucia, SMlippman, HLParnes, WBSisaacs, CGDrake, AMDeMarzo, EAPlatz. ProstateCancerandProstaticDiseases, submitted 3/24/15.

Multiple Studies Long-term use of data and specimens collected on NCI-sponsored Cancer Prevention Clinical Trials through the Community Clinical Oncology Program (CCOP). LMinasian, CTang, DLWickervitch. Seminars in Oncology, under review (special invited issue: Progress and Infrastructure for Clinical Research: The NCI National Clinical Trials Network; guest editor: CDBlank).
SYMPTOM CONTROL & QUALITY OF LIFE COMMITTEE

Symptom Control and QOL Committee Co-Chairs:
Michael Fisch, M.D., M.PH.
James L. Wade, III, M.D.

Time/Location
Thursday, April 30, 2015
Room: Garden Room (Atrium Lobby Level)
5:00 p.m. - 7:00 p.m.

Agenda

Introductions
New Co-Chair Replacing Dr. Moinpour: Michael Fisch, M.D., M.P.H.

Vision and Future Directions (Dr. Fisch)

National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Workshop: Setting National Research Priorities (Dr. Wade)

*Brainstorming—what (if anything) is different now compared to the time of the NCORP grant prep?

*Discuss the role of palliative care (Special Guest: Dr. Tom Smith from Johns Hopkins)

*Discuss the role of gamification as a symptom intervention (possible guest: Eddie Gonzalez-Novoa, @survivor_games, www.thesurvivorgames.com)

Active Studies


Closed Studies


■ S1007, “A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/− Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-responsive and Her2-Negative Breast Cancer According to Recurrence Score (RS).” Drs. Gonzales-Angulo, Meric-Bernstam, Hortobagyi, and Albain. Activated: 1/15/11 (Clinical study remains open to accrual); Quality of Life and Economic Substudy permanently closed to accrual 12/1/12.

Concepts in Development

■ S1404, “A Phase III Randomized Study of MK03475 versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma.” Dr. Grossman. QOL Component to be added to developing study in Melanoma Committee.

■ S1503, “Randomized Phase II Multicenter Non-Inferiority Trial of Apixaban 2.5 mg BID versus Low Molecular Weight Heparin for Prevention of Thromboembolism in Patients Being Treated with an Immunomodulatory-Based Regimen for Multiple Myeloma.” Drs. Calverley and Meyers.

■ S1506, “Phase II Randomized Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab With or Without Paclitaxel in Her2+ Metastatic Breast Cancer (MBC).” Dr. Elias. (Breast Committee Study)

■ “A Phase II Randomized Placebo-Controlled Study to Evaluate the Use of vitamin K1(Reconval®k1) Topical Lotion in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors.” Drs. Wong, Ryan, Wade, and Moinpour.

■ “Cognitive Rehabilitation Intervention During Cancer Treatment: Emerging from the Haze.” Dr. Asher and Jamie Myers, Ph.D., R.N. Dr. Asher has pilot data from a quality improvement project at Cedars-Sinai Medical Center with plans for a pilot study at this institution.
SYMPTOM CONTROL & QUALITY OF LIFE COMMITTEE

- “Enhanced Recovery After surgery (ERAS) Following Radical Cystectomy and Urinary Diversion.” Dr. Daneshmand and Jamie Myers, R.N., Ph.D. Possible companion study to an ongoing SWOG bladder cancer surgical trial.

- “Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Dr. Hamilton-Reeves.

Other Studies with Symptom Control and QOL Component


- CTSU/A021202, “Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors.” Dr. Phan. Activated: 1/15/14.


- CTSU/B55, “A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.” Dr. Sharma. Activated: 7/3/14.


- CTSU/E1411, “Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab + Bendamustine Followed by Rituximab Consolidation (RB --> R); Arm B = Rituximab + B endamustine + Bortezomib Followed by Rituximab Consolidation (RBV --> R), Arm C = Rituximab + Bendamustine Followed by Lenalidomide + Rituximab Consolidation (RB --> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed by Lenalidomide + Rituximab Consolidation (RBV --> LR).” Dr. Till. Activated 6/15/12.


- CTSU/E1A11, “Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).” Dr. Zonder. Activated: 2/1/14.


- CTSU/E2906, “Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard
SYMPTOM CONTROL & QUALITY OF LIFE COMMITTEE

Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years).” Dr. Godwin. Activated: 8/15/12; Closed: 2/23/15.


- **CTSU/N107C**, “A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease.” Dr. Gaspar. Activated: 12/1/11.

- **CTSU/R0848**, “A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.” Dr. Philip. Activated: 12/15/09.

- **CTSU/R1010**, “A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma.” Dr. Leichman. Activated: 9/1/11.

Committee Process
Sign meeting attendance list
Communication issues

Announcements
NCORP Updates

Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts
- **S0927** Randomized placebo-controlled trial of omega-3-fatty acid for the control of aromatase inhibitor-induced musculoskeletal pain (S0927). DL Hershman, JM Unger, KD Crew, D Awad, SR Dakhil, J Gralow, H Greenlee, LM Minasian, C Till, JL Wade, FL Meyskens, CM Moinpour. *Journal of Clinical Oncology*, in press. [also under Breast Committee]


Submitted Manuscripts
EARLY THERAPEUTICS AND RARE CANCERS
COMMITTEE

Committee Leadership
Chair: Razelle Kurzrock, M.D.
Executive Officer: Christopher W. Ryan, M.D.
Statisticians: Megan Othus, Ph.D.
Melissa Plets, M.S.

Designates
Data Coordinators: Laura Kingsbury, M.R.T.
Christine McLeod

Oncology Research Professionals:
CRAs: Corrine Turrell, C.C.R.P.
Nurse: TBD
Pharmaceutical Science: Su-Fun Wong, Pharm.D.
Protocol Coordinator: Cara Laubach, M.I.I.M.

Early Therapeutics Liaisons
Breast Committee Liaison: George Somlo, M.D.
Genitourinary Committee Liaison: Shirish M. Gadgeel, M.D.
Lung Committee Liaison: Daruka Mahadevan, M.D., Ph.D.
Lymphoma Committee Liaison: Jeffrey A. Sosman, M.D.
Melanoma Committee Liaison: Frits van Rhee, M.D., Ph.D.
Myeloma Committee Liaison: Siu-Fun Wong, Pharm.D.

Time/Location
Thursday, April 30, 2015
Room: Seacliff B-D (Bay Level)
10:00 a.m. – 12:15 p.m.

Agenda
Introduction to Early Therapeutics - Razelle Kurzrock, M.D., Senior Deputy Center Director, UCSD Moores Cancer Center

Presentations:
10:10 – 10:45 a.m.: “New Developments in Early Therapeutics”, Monica Mita, MD, Associate Professor, Department of Medicine; Co-Director, Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center

10:45 – 11:20 a.m.: “Bayer HealthCare Oncology Pipeline and Lifecycle Management”, Scott Wilhelm, PhD, Global Medical Affairs Scientist, Medical Affairs Oncology, Bayer

11:20 – 11:40 a.m.: “Anti-CTLA-4 plus anti-PD-1 in Rare Tumors”, Sandip Patel, MD, Assistant Professor, UCSD Moores Cancer Center and Young K. Chae, MD, MPh, Assistant Professor, Northwestern University

11:40 a.m. – 12:00 p.m.: “A Trial Incorporating Upfront Targeted Therapy in Carcinoma of Unknown Primary”, Laurence H. Baker, D.O. and Erin F. Cobain, M.D., SWOG/University of Michigan

12:00 pm – 12:15 pm: “Open Panel Discussion/Questions and Answers”, Razelle Kurzrock, M.D. and Speakers

Proposed Studies


Active Studies
- CTSU/A071102, “A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed MGMT Promoter Hypermethylation.” Dr. Piccioni. Activated by Alliance: 1/28/14; Activated by SWOG: 4/1/15.

Closed Studies

Open Discussion
EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts


Submitted Manuscripts


GASTROINTESTINAL COMMITTEE

Committee Leadership
Chair: Howard S. Hochster, M.D.
Vice-Chair: Heinz-Josef Lenz, M.D.
Executive Officer: Christopher W. Ryan, M.D.
Statisticians: Katherine Guthrie, Ph.D.

Scientific Leadership
Gastroesophageal: Syma Iqbal, M.D.
Lawrence P. Leichman, M.D.
Scott A. Hundahl, M.D. (Surgical representative)

Pancreatic: Philip A. Philip, M.D., Ph.D.
Andrew M. Lowy, M.D. (Surgical representative)
Tanios Bekaii-Saab, M.D.
(Translational representative)

Hepatobiliary: Anthony B. El-Khoueiry, M.D.
Abby B. Siegel, M.D.
Syed Ahmad, M.D. (Surgical representative)

Colon: Philip J. Gold, M.D.
Wells A. Messersmith M.D.
Kevin G. Billingsley, M.D. (Surgical representative)

Translational Medicine: Wells A. Messersmith, M.D.
Heinz-Josef Lenz, M.D.

Drug Development: Ramesh Ramanathan, M.D.
Sunil Sharma, M.D.

Imaging: Anthony F. Shields, M.D., Ph.D.
David Shin-Kuo Lu, M.D.

Radiation Oncology: Lisa A. Kachnic, M.D.

Designates
Cancer Control Liaison: Jason A. Zell, D.O.
Data Coordinators: Stephanie Edwards
Christine McLeod
Brian Zeller

Oncology Research Professionals:
CRAs: Sandy Annis, C.C.R.P.
Rita Kaul, R.N., B.S.N.
Valerie A. Parks, R.N.

Nurses: Porsha James, M.P.H.
Florence Kurttilla
Craig Elg, Pharm.D.
Linda Lee-Gabel, Pharm.D.

Patient Advocate (Pancreatic): Porsha James, M.P.H.
Patient Advocate (Colon): Florence Kurttilla
Pharmaceutical Science: Craig Elg, Pharm.D.
Protocol Coordinator: Kimberly Kaberle

Time/Location
Friday, May 1, 2015
Room: Grand B Ballroom (Street Level)
4:00 p.m. - 6:00 p.m.

Agenda
Introduction. Howard Hochster, M.D., Yale University.

Gastroesophageal

Active Studies
- S1201, “A Randomized Phase II Pilot Study Prospectively Assigning Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer.” Drs. Iqbal and Lenz. Activated: 2/8/12.

Proposed Studies
- CTSU/RTOG 1010, “A Phase II Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma.” Dr. L. Leichman. Activated: 9/1/11.

Pancreatic

Active Studies

Proposed Studies
- CTSU/E2211, “A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors.” Dr. Wolin. Activated: 3/1/12.

- CTSU/RTOG 0848, “A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.” Dr. Philip. Activated: 12/15/09.
**GASTROINTESTINAL COMMITTEE**

**Proposed Studies**

**Closed**

**Hepatobiliary**

**Active Studies**
- S1310, “Randomized Phase II Trial of Single Agent MEK Inhibitor GSK11200212 vs. 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer.” Dr. Kim. Activated: 2/15/14.

**Closed Studies**

**Correlative Studies**
- S9008A, “Trial of Adjuvant Chemoradiation after Gastric Resection Adenocarcinoma, Phase III.” Dr. Shridhar.

**Rectal**

**Active Studies**

**Colon**

**Active Studies**

**Closed Studies**
- S1008, “A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.” Dr. Hochster. Activated: 7/1/14.

**Other**

**Active Studies**
- S1406, “Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer.” Dr. Kopetz. Activated: 11/14/15.
Other Proposed Studies

- Randomized Phase II Study of 2nd Line Therapy with FOLFIRI and PARPi ABT888 in Metastatic Pancreatic Cancer. Dr. Chiorean.

- Gemcitabine/nab-Paclitaxel Followed by SBRT +/- MK3475 as Neoadjuvant Therapy for Borderline Resectable Pancreatic Adenocarcinoma: A Randomized Phase II Study. Dr. Bekaii-Saab.

- Safety Run In Followed by Randomized Phase II Trial of AMG-337 + Sorafenib versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) in the First Line. Dr. El-Khoueiry.

- Randomized Phase II Trial of SGI-110 with Gemcitabine and Cisplatin versus Gemcitabine and Cisplatin Alone in Advanced Biliary Cancer. Dr. Siegel.

- A Randomized Phase II/III Study of Gemcitabine and Cisplatin followed by Capecitabine/Radiation versus Gemcitabine and Cisplatin Alone. Dr. El-Khoueiry.

- Randomized Phase II Study of FOLFOXIRI vs FOLFOX for High Risk Rectal Cancer. Dr. Kennecke.

Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts


Submitted Manuscripts

No publication information for this cycle.
GENITOURINARY COMMITTEE

Committee Leadership
Chair:
Ian M. Thompson, Jr., M.D.
Nicholas J. Vogelzang, M.D.
Christopher W. Ryan, M.D.
Cathy M. Tangen, Dr.P.H.
Melissa Plets, M.S.

Vice-Chair:

Executive Officer:
Christopher W. Ryan, M.D.

Statisticians:
Cathy M. Tangen, Dr.P.H.
Melissa Plets, M.S.

Scientific Leadership
Translational Medicine:
David J. McConkey, Ph.D.
David Raben, M.D.
Daniel J. Culkin, M.D.
Daniel W. Lin, M.D.
John D. Hazle, Ph.D.
Celestia S. Higano, M.D.
M. Scott Lucia, M.D.
Colin P.N. Dinney, M.D.
Neeraj Agarwal, M.D.

Radiation Oncology:

Surgery:

Imaging:

Medical Oncology:

Pathology:

Liaison to the SPORES:

Early Therapeutics:

Designates
Cancer Control:
Peter J. Van Veldhuizen, M.D.
Jean Barce
Austin Hamm
Brian Zeller

Data Coordinators:

Oncology Research Professionals:
CRAs:
Debra W. Christie, M.B.A.
Deborah A. Halk, R.N.

Nurses:
Rick Bangs (Bladder)
Tony Crispino (Prostate)

Patient Advocates:
Jorge G. Avila, Pharm.D.
Jesse Modlin, Pharm.D.

Pharmaceutical Science:

Protocol Coordinator:
Jennifer Scott

Renal Cell
Organ Site Chairs: Drs. Primo N. Lara, Jr. (Advanced) and Edward M. Messing (Local)

Priority Studies
■ S1500, “A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors in Metastatic Papillary Renal Carcinoma (PAPMET).” Dr. Pal.

Active Studies


Bladder
Organ Site Chairs: Drs. Daniel P. Petrylak (Advanced) and Seth P. Lerner (Local)

Priority Studies

Active Studies


Time/Location
Saturday, May 2, 2015
Room: Grand A Ballroom (Street Level)
9:30 a.m. - 12:30 p.m.

Agenda

“PCORI, A Structured Approach to Prioritizing Cancer Research Using Stakeholders and Value of Information.” Scott D. Ramsey, M.D., Ph.D., Fred Hutchinson Cancer Research Center

“Collaboration Between Brazil and SWOG.” Stenio de Cassio Zequi, M.D., Sociedade Brasileira de Urologia.
GENITOURINARY COMMITTEE

Prostate

Organ Site Chairs: Drs. David I. Quinn (Advanced) and Martin E. Gleave and David Raben (Local)

Priority Studies

■ “A Randomized Phase III Study of Dutasteride Alone Versus Dutasteride plus Pulsatile Enzalutamide in Men With Low to Intermediate Risk Adenocarcinoma of the Prostate.” Dr. Lowrance.

Active Studies


Closed Studies

■ S1014, “Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II.” Drs. Flaig and Hussain. Activated: 8/9/11; Closed 8/1/13.

Cancer Control

Organ Site Chair: Dr. Peter J. Van Veldhuizen

Active Studies


Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees.

Published/Accepted Manuscripts


Submitted Manuscripts

No publication information for this cycle.
LEUKEMIA COMMITTEE

Committee Leadership

Chair: Harry P. Erba, M.D., Ph.D.
Vice-Chair: Steven E. Coutre, M.D.
Executive Officer: Susan M. O’Brien, M.D.
Statisticians: Megan Othus, Ph.D.
Hongli Li, M.S.
Shannon McDonough, M.S.

Scientific Leadership

Translational Medicine: Jerald P. Radich, M.D.
Pathology: David R. Head, M.D.
Cytogenetics Liaison: Diane Roulston, Ph.D.
Min Fang, M.D., Ph.D.

Designates

Data Coordinators: Louise Highleyman
Laura Kingsbury, M.R.T.
Tracy Maher, C.C.R.P.

Oncology Research Professionals:

CRAs: Mary Lynn Rush, R.N., B.S.N.
Nurses: Keisha C. Humphries, R.N., B.S.N.

Patient Advocate: Michelle J. Worman, L.V.N.

Pharmaceutical Science:

Holly O. Chan, Pharm.D.
Joyce Lee, Pharm.D.

Protocol Coordinator: Cara Laubach, M.I.I.M.

Time/Location

Friday, May 1, 2015
Room: Grand C Ballroom (Street Level)
4:00 p.m. - 6:00 p.m.

Agenda

Introduction
Current Status of the Leukemia Committee

Presentation:

“Genetics, epigenetics and non-coding RNAs: can we design a molecular risk-adapted trial for older AML?” Guido Marcucci, MD
Director Gehr Leukemia Center, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope; Chief, Division of Hematopoietic Stem Cell and Leukemia Research.

AML/MDS Studies

Active Studies


■ S1203, “A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7 + 3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)” Drs. Garcia-Manero, Pagel, Radich, and Fang. Activated: 12/15/12.

■ CTSU/E2905, “Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alpha (Procrit®) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia.” Dr. Schiffer. Activated by ECOG: 1/29/09; Activated by SWOG: 2/15/09.

Closed Studies


■ CTSU/E2906, “Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years).” Dr. Godwin. Activated by ECOG: 12/28/10; Activated by SWOG: 8/15/12; Closed: 2/23/15.

ALL Studies

Active Studies

■ S1318, “A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ / ≤ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ / ≤ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL.” Drs. Advani and O’Dwyer. Activated 1/12/15.
LEUKEMIA COMMITTEE

- S1312, “A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia and Burkitt’s Leukemia).” Drs. Advani and Liedtke. Activated: 4/1/14.


Closed Studies

- S0805, “Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without allogenic stem cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study).” Drs. Ravandi, O’Brien, Forman, Ha, Wong, and Radich. Activated: 9/1/09; Closed: 10/1/13.

- CTSU/C10701, “A Phase II Study of Dasatinib (Sprycel®)(IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults ≥ 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG.” Dr. Liedtke. Activated by CALGB: 12/15/10; Activated by SWOG: 6/1/12; Closed: 11/14/14.

Active Studies

- CTSU/A041202, “A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL).” Dr. Coutre. Activated by Alliance: 12/9/13; Activated by SWOG: 12/15/13.


Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts


Submitted Manuscripts


LUNG COMMITTEE

Committee Leadership
Chair: David R. Gandara, M.D.
Vice-Chair: Stephen G. Swisher, M.D.
Executive Officer: Julie R. Gralow, M.D.
Statisticians: Mary Redman, Ph.D.
James Moon, M.S.
Shannon McDonough, M.S. (Lung MAP Protocol)

Scientific Leadership
Translational Medicine: Philip C. Mack, Ph.D.
Fred R. Hirsch, M.D., Ph.D.
Radiation Oncology: Laurie E. Gaspar, M.D.
Surgery: Stephen G. Swisher, M.D.
Imaging: Anthony F. Shields, M.D., Ph.D.
Medical Oncology: Friedrich D. Knollmann, M.D., Ph.D.
Pathology: Karen Kelly, M.D.
Developmental Therapeutics: Ignacio I. Wistuba, M.D.
Early Therapeutics: Roy S. Herbst, M.D., Ph.D.

Designates
Cancer Control Liaison: Gary E. Goodman, M.D.
Community Affiliate: Paul J. Hesketh, M.D.
Data Coordinators: Larry Kaye
Brian Zeller
Austin Hamm
Vicki Green
Monica Yee (Lung MAP Protocol)

Oncology Research Professionals:
CRAs: Courtney L. Williamson
Ginny M. Keeling, M.S.
Nurses: Kimberly M. Belzer, M.S., P.A.-C
Rosalie Zablocki, R.N.
Patient Advocate: Bonnie J. Addario
Pharmaceutical Science: Joyce Lee, Pharm.D.
Daniel L. Hertz, Pharm.D.
Protocol Coordinator: Gretchen E. Goetz, M.B.A.
Crystal Miwa (Lung MAP Protocol)

Time/Location
Friday, May 1, 2015
Room: Grand A Ballroom (Street Level)
3:30 p.m. - 6:30 p.m.

Agenda
Opening Remarks

Translational Medicine Session - Dr. Mack
Surgery Session - Dr. Swisher
Scientific Session: “Biomarkers: Strategies for Checkpoint Immunotherapies.” Naiyer, Rizvi, M.D., Columbia University Medical Center

Proposals in Development
- S1400G, “A Phase II/III Randomized Study of BMN 673 (Talazoparib) versus Docetaxel for Previously-Treated Homologous Recombination Deficiency Positive Patients with Squamous Cell Lung Cancer.” Drs. Owonikoko and Byers.
- Second Line Small Cell Lung Cancer Trial with BMN PARP Inhibitor.
- Neoadjuvant Trial with BMN PARP Inhibitor.
- “Strategies to Improve Lymph Node Examination of Non-Small Cell Lung Tumors (SILENT).” Dr. Osarogiagbon.
- “A Lung Cancer Registry of Patients Being Treated for Non-Small Cell Lung Cancer (NSCLC) at SWOG Institutions.” Dr. Wozniak.
- “Minimally Invasive Surgery vs. Surgery Including Open Lobectomy in Non-Small Cell Lung Cancer (MISSION).” Drs. Rice and Swisher.
- “Randomized Phase II Study of the TGF Beta1 Tyrosine Kinase Inhibitor to Reduce Radiation Pneumonitis and Fibrosis.” Dr. Gaspar.
- “Randomized Phase II Trial to Test the Efficacy of BIBF1120 in Combination with Cisplatin and Etoposide for Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer.” Drs. Heymach and Glisson.
- “A Biomarker Driven, Randomized Phase III Study Comparing MPDL3280A or Pemetrexed Maintenance After Carboplatin/Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).” Dr. Chiang.
- “A Randomized Phase II Trial of Erlotinib with or without Ganetespib in Second Line EGFR, kRAS, and ALK Wild Type NSCLC Patients with Adenocarcinoma.” Dr. Kelly.
LUNG COMMITTEE

Active Studies


- S1206 (8811), “A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC),” (NCI Study Number 8811).” Drs. Argiris, Cristea and Chen. Activated: 10/1/12.


- S0905, “A Phase I / Randomized Phase II Study of Cediranib (NSC #732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma.” Drs. Tsao, Vogelzang and Wistuba. Activated: 3/15/10; Phase I Closed: 8/1/11; Phase II Activated: 10/1/11.


Proposed Studies

- S1504, “Randomized Phase II Trial of Neoadjuvant Cisplatin-Pemetrexed with or without MPDL3280A in Resectable Malignant Pleural Mesothelioma.” Dr. Tsao.

Closed Studies

- S1400E, “A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for...
LUNG COMMITTEE


- S0819, “A Randomized, Phase III Study Comparing Carboplatin / Paclitaxel or Carboplatin / Paclitaxel / Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).” Drs. Herbst, Kim, Gandara, Semrad and Hirsch. Activated: 7/15/09; Closed: TBD.


Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts


Submitted Manuscripts

LYMPHOMA COMMITTEE

Committee Leadership
Chair: Jonathan W. Friedberg, M.D.
Vice-Chair: Sonali M. Smith, M.D.
Executive Officer: Susan M. O’Brien, M.D.
Statisticians: Michael LeBlanc, Ph.D.
Hongli Li, M.S.

Scientific Leadership
Translational Medicine: Owen A. O’Connor, M.D., Ph.D.
Radiation Oncology: Louis S. Constine, M.D.
Imaging: Oliver W. Press, M.D., Ph.D.
Pathology: Lawrence H. Schwartz, M.D.
Early Therapeutics: Lisa M. Rimsza, M.D.

Designates
Cancer Control: John W. Hayslip, M.D.
Data Coordinators: Jeri Jardine
Iris Syquia

Oncology Research Professionals:
CRAs: Ellen Chase
Erin M. Cebula, M.P.H.
Nurse: TBD
Patient Advocate: Hildy Dillon, M.P.H.
Pharmaceutical Science: Lara M. Au, Pharm.D.
Holly O. Chan, Pharm.D.
Protocol Coordinator: Megan Hardin

Time/Location
Saturday, May 2, 2015
Room: Grand C Ballroom (Street Level)
9:30 a.m. - 12:30 p.m.

Agenda
1. Report of ongoing studies: Drs. Persky, Amengual, Till, and Fanale
2. Clinical Trials Planning Meeting Highlights
   a. DLBCL: Dr. Smith
   b. Follicular lymphoma: Dr. Barr
   c. Mantle cell lymphoma: Dr. Barr
   d. Hodgkin lymphoma: Dr. Persky
   e. T-cell lymphoma: Dr. Fanale and O’Connor
3. Report of recently completed studies
   a. Long-term follow-up of early stage DLBCL: Dr. Stephens
   b. Intergroup Mantle cell lymphoma: Dr. Chen
   c. S0016A Vitamin D and follicular lymphoma: Dr. Friedberg
4. Accrual discussions: group
5. Review of past SWOG lymphoma contributions

Non-Hodgkin Lymphoma


- CTSU/E1411, “Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab + Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV → R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR).” Dr. Till. Activated: 5/22/12.

- CTSU/E1412, “Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma.” Dr. Amengual. Activated: 6/1/14.


Cancer Control Studies

LYMPHOMA COMMITTEE

Closed Studies

Publications

The publications below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts

Submitted Manuscripts
MELANOMA COMMITTEE

Committee Leadership
Chair: Antoni Ribas, M.D., Ph.D.
Vice-Chair: William E. Carson III, M.D.
Executive Officer: Christopher W. Ryan, M.D.
Statisticians: Megan Othus, Ph.D.
James Moon, M.S.
Michael Wu, Ph.D.

Scientific Leadership
Translational Medicine: William E. Carson III, M.D.
Radiation Oncology: Evan J. Wuthrick, M.D.
Surgery: Robert H.I. Andtbacka, M.D.
Imaging: Kenneth F. Grossman, M.D., Ph.D.
Martin Allen-Auerbach, M.D.

Medical Oncology:
Pathology: Lawrence E. Flaherty, M.D.
Jane L. Messina, M.D.

Non-Melanoma Skin Cancer:
Early Therapeutics: Jeffrey A. Sosman, M.D.

Designates
Cancer Control Liaison: Sancy Leachman, M.D., Ph.D.
Data Coordinator: Jennie Barrett

Oncology Research Professionals:
CRAs: Sandy Allten, R.N., O.C.N.
Nurses: Karen L. Mack, R.N.P.
Ann M. Lau Clarke, R.N., M.S.N.
Lisa S. Morgan, R.N., O.C.N.

Patient Advocate: Valerie Guild
Pharmaceutical Science: Linda Lee-Gabel, Pharm.D.
Ronald G. Kittson, Pharm.D.

Protocol Coordinator: Patricia O’Kane

Time/Location
Friday, May 1, 2015
Room: Seacliff B-D (Bay Level)
9:30 a.m. - 11:30 a.m.

Agenda

Scientific Presentation
“Assessment of immune cell-melanoma interactions to decide on how to treat melanoma”, Paul C. Tuneh, M.D., UCLA.

Discussion: “How should we decide the therapy for patients with advanced melanoma?”

Active Studies


Approved Concepts

■ ECOG EA6134, “A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma.” Drs. Atkins and Chmielowski.

Closed Studies

Proposed SWOG Coordinated Intergroup Studies
■ “A Phase II Study of PD-1 Blockade with Pembrolizumab in Patients with Locally Advanced and Metastatic Desmoplastic Melanoma.” Drs. Kendra and Hu-Lieskov.}

■ “A Phase II Study of PD-1 Blockade with Pembrolizumab in Patients with Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin.” Dr. Cowey.
MELANOMA COMMITTEE

Publications

The publications listed below are those that have been received in published, submitted or accepted form by the Group Chair’s Office since the Fall 2014 Meeting agenda booklet publication list.

Published/Accepted Manuscripts


Submitted Manuscripts

- **S0008** Does unknown primary melanoma have a better prognosis? Analysis from a randomized phase III adjuvant trial (SWOG S0008). VK Sondak, J Moon, WE Carson, JT Vetto, RJ Tuthill, M Othus, MB Atkins, JA Sosman, A Ribas, LE Flaherty. *Cancer*, pending resubmission 3/15.
Future Group Meeting Dates
Mark Your Calendar!

2015

— Oct 7-10 —
Chicago, IL

2016

— April 27-30 —
San Francisco, CA

— Sep 14-17 —
Chicago, IL

2017

— April 26-29 —
San Francisco, CA

— Oct 11-14 —
Chicago, IL

Check the SWOG website (swog.org) for updates!
Do you have a few minutes between meetings? Stop by the SWOG registration desk in the Grand Ballroom Foyer to check your e-mail and/or print your boarding pass!
## Spring 2015 Group Meeting Commercial Supporters*

### CME SUPPORTERS

<table>
<thead>
<tr>
<th>Platinum</th>
<th>Celgene</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gold</td>
<td>Eli Lilly &amp; Co. Novartis</td>
</tr>
<tr>
<td>Silver</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Bronze</td>
<td>Amgen AstraZeneca</td>
</tr>
</tbody>
</table>

### NON-CME SPONSORS

<table>
<thead>
<tr>
<th>Platinum</th>
<th>Takeda Oncology</th>
</tr>
</thead>
</table>

### EXHIBITORS

- Astellas
- Boehringer Ingelheim Pharmaceuticals
- Guardant Health
- Novartis
- Seattle Genetics

*Supporters as of March 31, 2015

---

We appreciate their support!